Study S002102
Effect and Safety of Semaglutide Once-weekly in East Asian Subjects With Overweight or Obesity
Included trial: extracted dataClinicalTrials.gov recordStudy Protocol (PDF)Statistical Analysis Plan (PDF)
Registration
Registered primary outcomes
- Change in Body Weight (%) [Baseline (week 0), week 68]
- Number of Participants Who Achieve (Yes/no): Body Weight Reduction More Than or Equal to 5% [At week 68]
Linked records (3)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0017452 | Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial. Kadowaki T, Obesity research & clinical practice | 2025 | Randomized trial | PMID 40189961DOI | cites ClinicalTrials.gov:NCT03811574; registry reference DERIVED:40189961 |
| R0022193 | Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Kadowaki T, The lancet. Diabetes & endocrinology | 2022 | Randomized trial | PMID 35131037DOI | cites ClinicalTrials.gov:NCT03811574; registry reference DERIVED:35131037 |
| R0020651 | Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Davies M, Lancet (London, England) | 2021 | Randomized trial | PMID 33667417DOI | registry reference RESULT:33667417 |